Lirilumab

Tax included
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
MedChemExpress 
HY-P99208

Data sheet

Size
Multiple sizes
Reactivity
Others
Application
Cancer-programmed cell death
CAS
1000676-41-4